An economic review of compliance with medication therapy in the treatment of schizophrenia

Psychiatric Services

Volumn 54, Issue 4, 2003, Pages 508-516

  Thieda, Patricia ^a   Beard, Stephen ^a   Richter, Anke ^a   Kane, John ^b,c  

^a RTI HEALTH SOLUTIONS   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; DRUG COST; EMBASE; HEALTH CARE COST; HUMAN; MEDICAL LITERATURE; MEDLINE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PUBLICATION; RELAPSE; SCHIZOPHRENIA; SCISEARCH;

ANTIPSYCHOTIC AGENTS; COST OF ILLNESS; DIRECT SERVICE COSTS; EVALUATION STUDIES; HEALTH CARE COSTS; HUMANS; PATIENT COMPLIANCE; SCHIZOPHRENIA; SELF ADMINISTRATION; TREATMENT REFUSAL;

EID: 0037527741     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.54.4.508     Document Type: Article

References (30)

1. Warner B, de Girolamo G: Epidemiology of Mental Disorders and Psychosocial Problems: Schizophrenia. Geneva, World Health Organization, 1995
2. Rice DP: The economic impact of schizophrenia. Journal of Clinical Psychiatry 60(suppl 1):4-6, 1999
3. Mental illness in America (information provided by National Institute of Mental Health). Apples for Health, vol 1, no 33, Jan 14, 2000. Available at www.applesforhealth.com/illamerical.html 2002
4. Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophrenia Bulletin 21:419-429, 1995
5. Cramer JA, Rosenheck R: Compliance with medication regimens for mental and physical disorders. Psychiatric Services 49:196-201, 1998
6. Chakos M, Lieberman J, Hoffman E, et al: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158:518-526, 2001
7. Davies A, Langley PC, Keks NA, et al: Risperidone versus haloperidol: II. cost-effectiveness. Clinical Therapeutics 20:196-213, 1998
8. Dolder CR, Lacro JP, Dunn LB, et al: Antipsychotic medication adherence: is there a difference between typical and atypical agents? American Journal of Psychiatry 159:103-108, 2002
9. Gaebel W: Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. International Clinical Psychopharmacology 12 (suppl 1):S37-S42, 1997
10. Hamilton SH, Revicki DA, Edgell ET, et al: Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial. Pharmacoeconomics 15:469-480, 1999
11. Luchins DJ, Hanrahan P, Shinderman M, et al: Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends. Psychiatric Services 49:1034-1038, 1998
12. Mojtabai R, Lavelle J, Gibson PJ, et al: Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatric Services 53:337-339, 2002
13. Olfson M, Mechanic D, Hansell S, et al: Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services 51:216-222, 2000
14. Rastogi SC, Mynors-Wallace LM: Outcome of clozapine treatment for patients with treatment-resistant schizophrenia in a local clinical service. Psychiatric Bulletin 24:127-129, 2000
15. Rosenheck R, Cramer J, Xu W, et al: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia: Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New England Journal of Medicine 337:809-815, 1997
16. Rosenheck R, Chang S, Choe Y, et al: Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. Journal of Clinical Psychiatry 61:382-386, 2000
17. Costa e Silva JA, Alvarez N, Mazzoti G, et al: Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. Journal of Clinical Psychopharmacology 21:375-381, 2001
18. Svarstad BL, Shireman TI, Sweeney JK: Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services 52:805-811, 2001
19. Weiden P, Aquila R, Standard J: Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry 57(suppl 11):53-60, 1996
20. Dixon L: Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research 35(suppl):S93-S100, 1999
21. Kane JM: What can we achieve by implementing a compliance-improvement program? International Clinical Psychopharmacology 12(suppl):S43-S46, 1997
22. Rabinowitz J, Lichtenberg P, Kaplan Z, et al: Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. American Journal of Psychiatry 158:266-269, 2001
23. Carter CS, Mulsant BH, Sweet RA, et al: Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Psychopharmacology Bulletin 31:719-725, 1995
24. Essock SM, Frisman LK, Covell NH, et al: Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Archives of General Psychiatry 57:987-994, 2000
25. Finley PR, Sommer BR, Corbitt JL, et al: Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacology Bulletin 34:75-81, 1998
26. Glazer WM, Ereshefsky L: A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. Journal of Clinical Psychiatry 57:337-345, 1996
27. Palmer CS, Revicki DA, Genduso LA, et al: A cost-effectiveness clinical decision analysis model for schizophrenia. American Journal of Managed Care 4:345-355, 1998
28. Almond S, O'Donnell O: Cost analysis of the treatment of schizophrenia in the UK: a simulation model comparing olanzapine, risperidone, and haloperidol. Pharamcoeconomics 17:383-389, 2000
29. Maynard A, Bloor K: Building castles on sands or quicksands? The strengths and weaknesses of economic evaluation in pharmaceuticals. British Journal of Psychiatry 36(suppl):12-18, 1998
30. Neumann PJ: Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment. Journal of Clinical Psychiatry 60(suppl 3):9-14, 1999